Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a multi-agent chemotherapy and immunotherapy combination used primarily in clinical trials for advanced gastrointestinal cancers, notably pancreatic cancer. The regimen includes: - **Liposomal Irinotecan**: A topoisomerase I inhibitor encapsulated in a liposome to enhance delivery and reduce toxicity. - **Oxaliplatin**: A platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. - **5-Fluorouracil**: An antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Calcium Folinate (Leucovorin)**: Enhances the efficacy of 5-fluorouracil by stabilizing its binding to thymidylate synthase. - **Camrelizumab**: A monoclonal antibody targeting PD‑1, acting as an immune checkpoint inhibitor. The combination aims to maximize cytotoxic effects on tumor cells while leveraging immune modulation. It is being investigated for borderline resectable pancreatic cancer and other solid tumors[1][2][4].
- Brand names
- OnivydeAiRuiKaEloxatin
- Other names
- FOLFIRIFOLFOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + oxaliplatin + 5-fluorouracil + calcium folinate + camrelizumab.